National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Access to Care (1)
- Adverse Drug Events (ADE) (4)
- Arthritis (1)
- Chronic Conditions (1)
- Clinical Decision Support (CDS) (1)
- Electronic Health Records (EHRs) (1)
- Healthcare Costs (2)
- (-) Hepatitis (10)
- Human Immunodeficiency Virus (HIV) (3)
- (-) Medication (10)
- Outcomes (1)
- Patient Adherence/Compliance (2)
- Patient Safety (3)
- Prevention (1)
- Risk (1)
- Screening (1)
- Shared Decision Making (1)
- Vulnerable Populations (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 10 of 10 Research Studies DisplayedLo Re VR, Zeldow B, Kallan MJ
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.
This cohort study was conducted to determine if cumulative mitochondrial toxic nucleoside reverse transcriptase inhibitors (mtNRTI) use increased the risk of hepatic decompensation and death among patients coinfected with human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). The findings suggest that cumulative mtNRTI use may increase the risk of hepatic decompensation and death in HIV/HCV coinfection and should be avoided when alternatives exist for HIV/HCV patients.
AHRQ-funded; HS018372.
Citation: Lo Re VR, Zeldow B, Kallan MJ .
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.
Pharmacoepidemiol Drug Saf 2017 Oct;26(10):1172-81. doi: 10.1002/pds.4258..
Keywords: Adverse Drug Events (ADE), Hepatitis, Human Immunodeficiency Virus (HIV), Medication, Patient Safety
Schmajuk G, Tonner C, Trupin L
Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab.
Hepatitis B virus (HBV) reactivation in the setting of rituximab use is a potentially fatal but preventable safety event. The rate of HBV screening and proportion of patients at risk who receive antiviral prophylaxis in patients initiating rituximab is unknown. This study found wide variations in hepatitis B screening practices among patients receiving rituximab, resulting in unnecessary risks to patients.
AHRQ-funded; HS023558; HS024412.
Citation: Schmajuk G, Tonner C, Trupin L .
Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab.
Medicine 2017 Mar;96(13):e6528. doi: 10.1097/md.0000000000006528.
.
.
Keywords: Hepatitis, Electronic Health Records (EHRs), Medication, Prevention, Patient Safety
Beckman AL, Bilinski A, Boyko R
New hepatitis C drugs are very costly and unavailable to many state prisoners.
This study found that in the forty-one states whose departments of corrections reported data, 106,266 inmates (10 percent of their prisoners) were known to have hepatitis C on or about January 1, 2015. Only 949 of those inmates were being treated. Prices for a twelve-week course of direct-acting antivirals such as sofosbuvir and the combination drug ledipasvir/sofosbuvir varied widely as of September 30, 2015 ($43,418-$84,000 and $44,421-$94,500, respectively).
AHRQ-funded; HS000055.
Citation: Beckman AL, Bilinski A, Boyko R .
New hepatitis C drugs are very costly and unavailable to many state prisoners.
Health Aff 2016 Oct;35(10):1893-901. doi: 10.1377/hlthaff.2016.0296.
.
.
Keywords: Access to Care, Healthcare Costs, Hepatitis, Medication, Vulnerable Populations
Tetrault JM, Tate JP, Edelman EJ
Hepatic safety of buprenorphine in HIV-Infected and uninfected patients with opioid use disorder: the role of HCV-infection.
The purpose of this paper was to examine risk for buprenorphine (BUP)-associated hepatotoxicity among individuals with HIV and HCV. The authors found that liver enzymes and total bilirubin are rarely elevated in HIV-infected and uninfected patients receiving BUP, and that the risk of hepatotoxicity was greater in individuals infected with HIV, HCV, or HIV/HCV co-infection, who may benefit from increased monitoring.
AHRQ-funded; HS021112; HS018372.
Citation: Tetrault JM, Tate JP, Edelman EJ .
Hepatic safety of buprenorphine in HIV-Infected and uninfected patients with opioid use disorder: the role of HCV-infection.
J Subst Abuse Treat 2016 Sep;68:62-7. doi: 10.1016/j.jsat.2016.06.002.
.
.
Keywords: Adverse Drug Events (ADE), Hepatitis, Human Immunodeficiency Virus (HIV), Medication, Risk
LaFleur J, Hoop R, Korner E
Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C.
The researchers determined whether selected patient characteristics predicted discontinued therapy for reasons other than lack of efficcacy (non-LOE) using national databases of U.S. veterans. They found that predictors of greatest magnitude included comorbidities of myocardial infarction/congestive heart failure, renal disease, platelets 100/mm or more, Black race, albumin 3.5 mg/dl or more, sleep aid use, and poor persistence with antidepressants and antihypertensive agents.
AHRQ-funded; HS018582.
Citation: LaFleur J, Hoop R, Korner E .
Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C.
Gastroenterol Nurs 2015 Nov-Dec;38(6):417-28. doi: 10.1097/sga.0000000000000214.
.
.
Keywords: Chronic Conditions, Hepatitis, Medication, Patient Adherence/Compliance
Butt AA, Yan P, Shaikh OS
Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
This study sought to quantify treatment response, tolerability and occurrence of haematologic adverse events among persons treated with boceprevir (B0C)- and telaprevir (TPV)-containing regimens and compare them with historic controls treated with pegylated interferon/ribavirin (PEG/RBV) in actual clinical settings. It found that use of BOC- and TPV-containing regimens is superior to PEG/RBV for treatment of HCV genotype 1-infected persons.
AHRQ-funded; HS018372.
Citation: Butt AA, Yan P, Shaikh OS .
Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
J Viral Hepat 2015 Sep;22(9):691-700. doi: 10.1111/jvh.12375..
Keywords: Adverse Drug Events (ADE), Hepatitis, Medication
Pho MT, Jensen DM, Meltzer DO
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
The researchers developed a decision model to quantify the trade-offs between immediate, interferon-containing therapy and delayed, interferon-free therapy for patients with chronic, genotype 1 HCV infection. They found that compared to one-time immediate treatment with the interferon-containing regimen, delayed treatment with the interferon-free regimen in 1 year resulted in longer life expectancy.
AHRQ-funded; HS022433.
Citation: Pho MT, Jensen DM, Meltzer DO .
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
J Viral Hepat 2015 Aug;22(8):630-8. doi: 10.1111/jvh.12412..
Keywords: Clinical Decision Support (CDS), Shared Decision Making, Hepatitis, Medication, Outcomes
Burton MJ, Curtis JR, Yang S
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
The researchers evaluated the safety of current treatment regimens for patients with rheumatoid arthritis (RA) and HBV in a large US cohort. They found a low rate of hepatotoxicity among a large cohort of US veterans with RA and HBV infection who were prescribed conventional RA therapies. Also, there were comparable rates of hepatotoxicity between biologic and nonbiologic disease-modifying anti-rheumatic drugs.
AHRQ-funded; HS023710.
Citation: Burton MJ, Curtis JR, Yang S .
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
Arthritis Res Ther 2015 May 22;17:136. doi: 10.1186/s13075-015-0628-z..
Keywords: Arthritis, Patient Safety, Medication, Hepatitis, Adverse Drug Events (ADE)
Zhang S, Rust G, Cardarelli K
Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection.
The purpose of this study was to quantify the clinical and economic benefits of adherence to anti-retroviral therapy (ART), with a special focus on the subset of Medicaid enrollees with both HIV and HCV coinfection. It found that high-adherence to ART among Medicaid-enrolled patients with HIV and HCV coinfection is achievable – over 60 percent of such patients in this data-set had over 95 percent adherence to their ART.
AHRQ-funded; HS022444.
Citation: Zhang S, Rust G, Cardarelli K .
Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection.
AIDS Care 2015;27(7):829-35. doi: 10.1080/09540121.2015.1021745..
Keywords: Hepatitis, Human Immunodeficiency Virus (HIV), Patient Adherence/Compliance, Medication
Kim DD, Hutton DW, Raouf AA
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
The researchers examined the cost-effectiveness of screening and treatment for HCV infection for asymptomatic, average-risk adults using a Markov decision analytic model. They found that, in Egypt, implementing a screening program using triple-therapy treatment (sofosbuvir with pegylated interferon and ribavirin) was dominant compared with no screening because it would have lower total costs and improve health outcomes.
AHRQ-funded; HS013853.
Citation: Kim DD, Hutton DW, Raouf AA .
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Glob Public Health 2015;10(3):296-317. doi: 10.1080/17441692.2014.984742..
Keywords: Hepatitis, Screening, Healthcare Costs, Medication